ABSTRACT
The 59th American Society of Hematology (ASH) Annual Meeting is known as the most powerful hematological meeting around the world. The outcomes in the meeting showed the progress of current hematological diseases from the fundamental research to the clinical practice, from the diagnosis to the treatment. The 59th ASH Annual Meeting covered the contents from the improvement of the formal treatment of acute myelogenous leukemia to the strategies of the aggressive B-cell lymphoma, from the prospect on myelodysplastic syndromes to the influence of biological features on the treatment strategies of indolent lymphoma, from the individualized treatment of chronic lymphocytic leukemia to the study on acquired or hereditary bone marrow failure. The inspiring outcomes from the scholars in China have gained good reputations from the international.
ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma in adults, which is a highly heterogeneous of lymphoma with different biological characteristics, clinical manifestations, response to treatment and different prognosis for different patients. Although the curative rate of DLBCL patients has been improved because of the immunotherapy based on the R-CHOP treatment, 40％of patients will be resistant to the treatment or relapse after the remission at the early stage with poor prognosis. This article summarizes the recent progress of DLBCL including new molecular typing, new target drug development and treatment of relapsed /refractory patients according to the 59th American Society of Hematology Annual Meeting.